(Q56779471)

English

Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy

No description defined

In more languages

Statements

scholarly article

0 references

Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy (English)

0 references

cancer research

0 references

1 reference

based on heuristic

inferred from title

metastatic breast cancer

1 reference

based on heuristic

inferred from title

object named as

Marco Colleoni

9

0 references

Patrick Maisonneuve

object named as

Patrick Maisonneuve

6

0 references

author name string

Maria Teresa Sandri

1

0 references

Harriet Ann Johansson

2

0 references

Laura Zorzino

3

0 references

Michela Salvatici

4

0 references

Rita Passerini

5

0 references

Andrea Rocca

7

0 references

Giulia Peruzzotti

8

0 references

language of work or name

0 references

publication date

2007

0 references

number of pages

9

1 reference

based on heuristic

inferred from page(s)

0 references

110

0 references

3

0 references

509-517

0 references

Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22825

21 January 2018

Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22825

21 January 2018

The ErbB signaling network: receptor heterodimerization in development and cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22825

7 January 2021

based on heuristic

inferred from DOI database lookup

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22825

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22825

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22825

7 January 2021

based on heuristic

inferred from DOI database lookup

Potential Clinical Utility of Serum HER-2/neu Oncoprotein Concentrations in Patients with Breast Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22825

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of C-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22825

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22825

7 January 2021

based on heuristic

inferred from DOI database lookup

Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22825

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22825

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22825

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22825

7 January 2021

based on heuristic

inferred from DOI database lookup

Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22825

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22825

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib (ZD1839) combined with weekly epirubicin in patients with metastatic breast cancer: a phase I study with biological correlate.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22825

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22825

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum EGFR levels and efficacy of trastuzumab-based therapy in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22825

7 January 2021

based on heuristic

inferred from DOI database lookup

Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22825

7 January 2021

based on heuristic

inferred from DOI database lookup

Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22825

7 January 2021

based on heuristic

inferred from DOI database lookup

Monitoring therapy by serum HER-2/neu

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22825

7 January 2021

based on heuristic

inferred from DOI database lookup

The influence of chemotherapy on survival after recurrence in breast cancer--a population-based study of patients treated in the 1950s, 1960s and 1970s

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22825

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiangiogenic therapy: a universal chemosensitization strategy for cancer?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22825

7 January 2021

based on heuristic

inferred from DOI database lookup

Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22825

7 January 2021

based on heuristic

inferred from DOI database lookup

Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22825

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22825

7 January 2021

based on heuristic

inferred from DOI database lookup

Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22825

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide As Primary Systemic Treatment in Elderly Breast Cancer Patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22825

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22825

7 January 2021

based on heuristic

inferred from DOI database lookup

ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22825

7 January 2021

based on heuristic

inferred from DOI database lookup

Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22825

7 January 2021

based on heuristic

inferred from DOI database lookup

Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22825

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22825

7 January 2021

based on heuristic

inferred from DOI database lookup

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22825

7 January 2021

based on heuristic

inferred from DOI database lookup

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22825

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.22825

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q56779471&oldid=1767721993"